Smart Nanomaterials for Targeted Stem Cell Modulation: Safety, Efficacy and GMP Compliance
Main Article Content
Abstract
Smart nanomaterials have emerged as a promising strategy to enhance the therapeutic potential of stem cell based regenerative medicine. Among these, stimuli-responsive nanocarriers offer precise spatiotemporal control over drug delivery and cellular modulation by responding to specific biological or physicochemical triggers such as pH, temperature, enzymes, and redox gradients. These advanced systems improve stem cell homing, survival, differentiation, and immunomodulatory functions while minimizing systemic toxicity. Despite their significant advantages, concerns related to safety, including cytotoxicity, immunogenicity, biodistribution, and long-term toxicity, remain critical barriers to clinical translation. Furthermore, the integration of nanotechnology with stem cell therapy introduces additional complexity in manufacturing, requiring strict adherence to Good Manufacturing Practice (GMP) standards to ensure product quality, reproducibility, and safety. This review critically evaluates the design, mechanisms, efficacy, and safety of responsive nanocarriers for targeted stem cell modulation. It also examines current GMP requirements, regulatory challenges, and translational hurdles associated with these hybrid systems. Finally, future perspectives focusing on scalable manufacturing, standardized regulatory frameworks, and advanced biomimetic nanomaterials are discussed to accelerate clinical adoption.
Article Details
Section
How to Cite
References
[1] J. Shi, P. W. Kantoff, R. Wooster, and O. C. Farokhzad, "Cancer nanomedicine: progress, challenges and opportunities," (in eng), Nat Rev Cancer, vol. 17, no. 1, pp. 20-37, Jan 2017, doi: 10.1038/nrc.2016.108.
[2] A. Trounson and C. McDonald, "Stem Cell Therapies in Clinical Trials: Progress and Challenges," (in eng), Cell Stem Cell, vol. 17, no. 1, pp. 11-22, Jul 2 2015, doi: 10.1016/j.stem.2015.06.007.
[3] J. Galipeau and L. Sensébé, "Mesenchymal Stromal Cells: Clinical Challenges and Therapeutic Opportunities," (in eng), Cell Stem Cell, vol. 22, no. 6, pp. 824-833, Jun 1 2018, doi: 10.1016/j.stem.2018.05.004.
[4] M. J. Mitchell, M. M. Billingsley, R. M. Haley, M. E. Wechsler, N. A. Peppas, and R. Langer, "Engineering precision nanoparticles for drug delivery," (in eng), Nat Rev Drug Discov, vol. 20, no. 2, pp. 101-124, Feb 2021, doi: 10.1038/s41573-020-0090-8.
[5] S. Mura, J. Nicolas, and P. Couvreur, "Stimuli-responsive nanocarriers for drug delivery," (in eng), Nat Mater, vol. 12, no. 11, pp. 991-1003, Nov 2013, doi: 10.1038/nmat3776.
[6] A. C. Anselmo and S. Mitragotri, "Nanoparticles in the clinic: An update," (in eng), Bioeng Transl Med, vol. 4, no. 3, p. e10143, Sep 2019, doi: 10.1002/btm2.10143.
[7] A. Y. Rwei, W. Wang, and D. S. Kohane, "Photoresponsive nanoparticles for drug delivery," (in eng), Nano Today, vol. 10, no. 4, pp. 451-467, Aug 1 2015, doi: 10.1016/j.nantod.2015.06.004.
[8] B. Fadeel et al., "Advanced tools for the safety assessment of nanomaterials," (in eng), Nat Nanotechnol, vol. 13, no. 7, pp. 537-543, Jul 2018, doi: 10.1038/s41565-018-0185-0.
[9] M. M. Islam and S. Raikwar, "Enhancement of Oral Bioavailability of Protein and Peptide by Polysaccharide-based Nanoparticles," (in eng), Protein Pept Lett, vol. 31, no. 3, pp. 209-228, 2024, doi: 10.2174/0109298665292469240228064739.
[10] B. S. Pattni, V. V. Chupin, and V. P. Torchilin, "New Developments in Liposomal Drug Delivery," (in eng), Chem Rev, vol. 115, no. 19, pp. 10938-66, Oct 14 2015, doi: 10.1021/acs.chemrev.5b00046.
[11] H. K. Makadia and S. J. Siegel, "Poly Lactic-co-Glycolic Acid (PLGA) as Biodegradable Controlled Drug Delivery Carrier," (in eng), Polymers (Basel), vol. 3, no. 3, pp. 1377-1397, Sep 1 2011, doi: 10.3390/polym3031377.
[12] A. P. Dias et al., "Dendrimers in the context of nanomedicine," International Journal of Pharmaceutics, vol. 573, p. 118814, 2020/01/05/ 2020, doi: https://doi.org/10.1016/j.ijpharm.2019.118814.
[13] E. C. Dreaden, A. M. Alkilany, X. Huang, C. J. Murphy, and M. A. El-Sayed, "The golden age: gold nanoparticles for biomedicine," (in eng), Chem Soc Rev, vol. 41, no. 7, pp. 2740-79, Apr 7 2012, doi: 10.1039/c1cs15237h.
[14] R. Li, Y. He, S. Zhang, J. Qin, and J. Wang, "Cell membrane-based nanoparticles: a new biomimetic platform for tumor diagnosis and treatment," Acta Pharmaceutica Sinica B, vol. 8, no. 1, pp. 14-22, 2018/01/01/ 2018, doi: https://doi.org/10.1016/j.apsb.2017.11.009.
[15] D. Schmaljohann, "Thermo- and pH-responsive polymers in drug delivery," (in eng), Adv Drug Deliv Rev, vol. 58, no. 15, pp. 1655-70, Dec 30 2006, doi: 10.1016/j.addr.2006.09.020.
[16] V. Gupta et al., "Nanotechnology-driven cancer therapies for precision oncology: advances and clinical outlook," International Journal of Nanomedicine, pp. 1-33, 2026.
[17] X. Guo, Y. Cheng, X. Zhao, Y. Luo, J. Chen, and W. E. Yuan, "Advances in redox-responsive drug delivery systems of tumor microenvironment," (in eng), J Nanobiotechnology, vol. 16, no. 1, p. 74, Sep 22 2018, doi: 10.1186/s12951-018-0398-2.
[18] M. Mendes, J. J. Sousa, A. Pais, and C. Vitorino, "Targeted Theranostic Nanoparticles for Brain Tumor Treatment," (in eng), Pharmaceutics, vol. 10, no. 4, Oct 9 2018, doi: 10.3390/pharmaceutics10040181.
[19] H. Naderi-Meshkin, A. R. Bahrami, H. R. Bidkhori, M. Mirahmadi, and N. Ahmadiankia, "Strategies to improve homing of mesenchymal stem cells for greater efficacy in stem cell therapy," (in eng), Cell Biol Int, vol. 39, no. 1, pp. 23-34, Jan 2015, doi: 10.1002/cbin.10378.
[20] X. Yang, Y. Li, X. Liu, W. He, Q. Huang, and Q. Feng, "Nanoparticles and their effects on differentiation of mesenchymal stem cells," (in eng), Biomater Transl, vol. 1, no. 1, pp. 58-68, 2020, doi: 10.3877/cma.j.issn.2096-112X.2020.01.006.
[21] A. A. Aljabali et al., "Nanomaterials and Their Impact on the Immune System," (in eng), Int J Mol Sci, vol. 24, no. 3, Jan 19 2023, doi: 10.3390/ijms24032008.
[22] W. L. Murphy, T. C. McDevitt, and A. J. Engler, "Materials as stem cell regulators," (in eng), Nat Mater, vol. 13, no. 6, pp. 547-57, Jun 2014, doi: 10.1038/nmat3937.
[23] S. Farjaminejad, R. Farjaminejad, and F. Garcia-Godoy, "Nanoparticles in Bone Regeneration: A Narrative Review of Current Advances and Future Directions in Tissue Engineering," (in eng), J Funct Biomater, vol. 15, no. 9, Aug 23 2024, doi: 10.3390/jfb15090241.
[24] M. Wang, G. Mi, D. Shi, N. Bassous, D. Hickey, and T. Webster, "Nanotechnology and Nanomaterials for Improving Neural Interfaces," Advanced Functional Materials, vol. 28, p. 1700905, 03/21 2018, doi: 10.1002/adfm.201700905.
[25] X. Cui et al., "Bioderived Nanoparticles for Cardiac Repair," ACS Nano, vol. 18, no. 36, pp. 24622-24649, 2024/09/10 2024, doi: 10.1021/acsnano.3c07878.
[26] Y. Li, C. Xu, and C. Lei, "The Delivery and Activation of Growth Factors Using Nanomaterials for Bone Repair," (in eng), Pharmaceutics, vol. 15, no. 3, Mar 22 2023, doi: 10.3390/pharmaceutics15031017.
[27] K. A. Whitehead, R. Langer, and D. G. Anderson, "Knocking down barriers: advances in siRNA delivery," (in eng), Nat Rev Drug Discov, vol. 8, no. 2, pp. 129-38, Feb 2009, doi: 10.1038/nrd2742.
[28] J. M. Hare et al., "Comparison of allogeneic vs autologous bone marrow–derived mesenchymal stem cells delivered by transendocardial injection in patients with ischemic cardiomyopathy: the POSEIDON randomized trial," (in eng), Jama, vol. 308, no. 22, pp. 2369-79, Dec 12 2012, doi: 10.1001/jama.2012.25321.
[29] C. L. Ventola, "Progress in Nanomedicine: Approved and Investigational Nanodrugs," (in eng), P t, vol. 42, no. 12, pp. 742-755, Dec 2017.